Hamburg, Germany, December 5, 2022 /PRNewswire/ — apoQlar, a German medical technology company, today announced that it has received FDA 510(k) Class II clearance for VSI HoloMedicine®, a pioneering mixed reality software device that enables surgeons to plan complex procedures using the power of immersive 3D holographic technology. With this authorization, the USA becomes 30^the country for apoQlar to receive medical certification in. apoQlar will extend its distribution of VSI HoloMedicine® in the USA for clinical use through its subsidiary in Miami Floridawith availability scheduled for the second quarter of 2023.

After this great achievement, apoQlar is now raising a Serie A round, his first…